99.6% PURITY
TRIPLE-AGONIST METABOLIC CATALYST
Retatrutide
10 mg vial · lyophilized
Next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase II trials report some of the largest weight-loss outcomes observed in the incretin class to date.
Half-Life
~6 days (weekly dosing)
Storage
Lyophilized: 2–8 °C. Reconstituted: 2–8 °C, use within 30 days.
Next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase II trials report some of the largest weight-loss outcomes observed in the incretin class to date.
View Certificate of Analysis (COA)Who it's for
Metabolic researchers exploring next-generation incretin pharmacology and obesity intervention.
Key things to know
- •Weekly subcutaneous dosing — long half-life smooths plasma concentration.
- •Slow titration is critical; rapid escalation causes nausea in clinical models.
- •Triple-receptor activity yields larger weight reduction than dual agonists in head-to-head data.
- •Monitor heart rate and hydration in extended-duration research.
Research Highlights
- •Phase II showed up to ~24% body weight reduction at 48 weeks (Eli Lilly, NEJM 2023)
- •Currently in Phase III obesity and MASH trials
